HYDERABAD, India, Aug. 26, 2021 /PRNewswire/ -- Sai Life Sciences, a leading global (CRO/ CDMO), today announced that it has become a signatory of the United Nations Global Compact (UNGC), the world's largest sustainability initiative. As a signatory, Sai Life Sciences has committed itself to adopting the Ten Principles of the UNGC on human rights, labour, environment and anti-corruption, reinforcing the company's to corporate responsibility and sustainability.

Making the announcement, Krishna Kanumuri, CEO & Managing Director said, "As we pursue our vision and business growth, we consciously integrate our social, environmental and governance responsibilities. We have committed ourselves to implement and to make them part of the strategy, culture and day-to-day operations of our company. This will help us in strengthening our sustainability agenda and also accelerate our progress towards achieving our (SDGs)."

Over the past two years, Sai Life Sciences has made significant investments and progress in advancing its Sustainability agenda as part of its organizational transformation initiative, Sai Nxt. Some of the notable highlights:

• Became the first India-headquartered company to join the .
• Joined ACS Green Chemistry Institute Pharmaceutical Roundtable () as an 'Associate Member'.
• Released its first in 2020 in line with the GRI framework
• Received the certifications for its R&D and manufacturing sites.
• Won the prestigious 21st 2020 by CII - Sohrabji Godrej Green Business Centre
• Received 5-Star rating for at the Confederation of Indian Industry (CII) South awards 2019 and 2020.

About Sai Life Sciences

Sai Life Sciences is a that works with innovator pharma and biotech companies globally, to accelerate the discovery, development and commercialisation of complex small molecules. For over two decades, Sai Life Sciences has consistently delivered high-quality, cost-effective solutions to its diverse customers spanning biotechs, small, mid and large pharma. Today, it has over 2200 employees across its facilities in India, UK and USA. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. .